Drug intelligence / Profile preview

CJ-004

Development stage: Unknown
Lead developer: Guangdong Xijie Pharmaceutical
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

CJ-004 is a nanocrystal formulation of the taxane **cabazitaxel**, developed by **Guangdong Xijie Pharmaceutical**. It is classified as a Class 2 improved new drug in China, utilizing nanotechnology to enhance the solubility and pharmacokinetic profile of the active ingredient. Cabazitaxel acts as a microtubule stabilizer by binding to **tubulin**, which prevents microtubule depolymerization and leads to cell cycle arrest and apoptosis. CJ-004 is currently in **Phase 1** clinical development for the treatment of advanced solid tumors, specifically **ovarian cancer** and **breast cancer**.

Other names: cabazitaxel nanocrystal injection

Targets

PDE5 (Phosphodiesterase 5A)

Beyond the preview

Go deeper on CJ-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CJ-004.

Explore the full profile